Forget about it.

You may have forgotten about two recent provocative papers published in 2016 and 2017 by Nead and colleagues that described an increased risk of dementia, specifically Alzheimer dementia (AD), in men with prostate cancer treated with androgen deprivation therapy (ADT). What's more, this risk appeared proportional to duration of treatment. But the Nead studies had some big limitations, including a relatively small number of events and the fact that the data was electronically extracted from medical documentation. Most recently, a study out in JCO this week assessed a huge Medicare population of >1 million men to demonstrate no increased risk of AD and a small 1% increase in risk of any dementia. And there was no apparent dose-response relationship. Looks like you can order ADT but hold the AD.